Clinical Trial Detail

NCT ID NCT02356159
Title Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

acute lymphoblastic leukemia

acute myeloid leukemia

multiple myeloma

Therapies

Cytarabine + Fludarabine

Palifermin

Prednisone

Filgrastim

Methotrexate + Sirolimus + Tacrolimus

Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate

Cyclophosphamide + Fludarabine

Rituximab

Age Groups: adult

Additional content available in CKB BOOST